Genomic Molecular Classification of CNS Malignancies

Area of Science:

• Neuro-oncology
• Genomics
• Molecular Biology

Background:

• Histopathologic grading of brain tumors has limitations in predicting tumor behavior and treatment response.
• Molecular studies have identified distinct genomic drivers crucial for understanding brain tumor biology.
• Advances in genetic and epigenetic analysis enable more precise tumor classification.

Purpose of the Study:

• To highlight the role of molecular biomarkers in improving the classification and management of central nervous system (CNS) tumors.
• To demonstrate how genomic and epigenetic profiling aids in distinguishing tumor entities and predicting outcomes.
• To emphasize the translation of molecular findings into clinical practice for patient benefit.

Main Methods:

• Utilizing genetic and epigenetic profiling techniques.
• Employing mutation-specific antibodies for accurate classification.
• Analyzing molecular drivers such as IDH1/2, ATRX, TP53, histone H3 genes, and MAPK pathway fusions.

Main Results:

• Molecular biomarkers offer superior prediction of tumor behavior and therapeutic response compared to histopathologic grading.
• Diffuse gliomas are classified based on IDH1/2, ATRX, and TP53 mutational status.
• Pediatric gliomas show distinct molecular drivers including histone H3 genes and MAPK pathway fusions.
• CNS tumors like ependymomas, medulloblastomas, and atypical teratoid/rhabdoid tumors are separated into distinct biological and clinical entities using profiling.
• Novel gene fusions and DNA methylation signatures enable accurate diagnosis of primitive neuroectodermal tumors.

Conclusions:

• Genomic classification is transforming CNS tumor diagnosis and management.
• Molecularly based patient management and clinical trials are becoming standard practice.
• Accurate molecular diagnosis leads to improved patient stratification and therapeutic strategies.